Nektar Therapeutics filings document the regulatory record of a Delaware clinical-stage biotechnology issuer with common stock listed on the Nasdaq Capital Market under NKTR. The company's 8-K reports cover financial results, Regulation FD clinical disclosures for rezpegaldesleukin, material definitive agreements, underwriting arrangements, at-the-market equity distribution mechanics, and shelf-registration-related offerings.
Proxy materials describe annual meeting matters, director elections, equity incentive plan authorization, auditor ratification, executive compensation votes, and governance procedures. Nektar's filing record also reflects capital-structure disclosures for common stock and pre-funded warrants, clinical-stage pipeline risks, research and development funding needs, and public-company controls tied to its immunology drug development business.
Nektar Therapeutics is asking stockholders to vote at its 2026 virtual annual meeting on June 4, 2026. Proposals include electing CEO Howard W. Robin to the board, amending the 2017 Performance Incentive Plan to add 3,000,000 shares, ratifying Ernst & Young LLP as auditor for 2026, and approving an advisory say-on-pay vote on executive compensation.
The proxy also details board structure, committee responsibilities, related-party review, and ownership data, including 29,679,647 common shares outstanding as of April 6, 2026, and major holders such as FMR LLC with 10.2% of the stock.
Nektar Therapeutics is raising new equity capital through an upsized underwritten public offering of 3,532,609 shares of common stock at $92.00 per share, with underwriters exercising a 30-day option for an additional 529,891 shares in full.
The company expects gross proceeds of about $325 million and estimates net proceeds of approximately $350.9 million after underwriting discounts and expenses. All shares are being sold by Nektar, and the deal is expected to close on April 23, 2026, subject to customary conditions.
Nektar plans to use the net proceeds for general corporate purposes, including research and development, clinical development such as Phase 3 trials for its lead candidate rezpegaldesleukin in atopic dermatitis and alopecia areata, and manufacturing costs to advance its drug pipeline.
Nektar Therapeutics is offering 3,532,609 shares of its common stock pursuant to a prospectus supplement, at a public offering price of $92.00 per share. The offering is expected to yield approximately $305.1 million in net proceeds before expenses (about $350.9 million if the underwriters exercise their full 30-day option for 529,891 additional shares). Shares outstanding used for this offering are stated as 29,679,647 shares as of April 1, 2026. The company intends to use proceeds for general corporate purposes, including research and development, clinical development (including Phase 3 trials for rezpegaldesleukin in atopic dermatitis and alopecia areata), and manufacturing costs to advance its drug candidates.
Nektar Therapeutics is offering $250,000,000 of common stock and, in lieu of shares for certain investors, pre-funded warrants exercisable for common stock, pursuant to a preliminary prospectus supplement dated April 20, 2026. The offering is part of a shelf registration and is subject to completion; proceeds are intended for general corporate purposes including research, clinical development and manufacturing for rezpegaldesleukin and other programs.
The company reported preliminary cash and marketable securities of approximately $741.7 million as of April 1, 2026 and completed an at-the-market program that raised about $110.0 million from 1,532,850 shares sold at a weighted average price of $71.76. Outstanding common shares used for offering calculations are 29,679,647 as of April 1, 2026.
Nektar Therapeutics furnished an update on its liquidity position. The company reported having approximately $741.7 million in cash and investments in marketable securities as of April 1, 2026. This figure is an estimate based on information available at that time and is not a full statement of operating results or overall financial position.
Nektar Therapeutics reported 52-week topline results from its Phase 2b REZOLVE-AA study of rezpegaldesleukin in severe-to-very-severe alopecia areata. In a 16-week blinded extension to week 52, 29% of patients on the 18 µg/kg dose and 31% on the 24 µg/kg dose achieved new SALT Score ≤20 responses, meaning at least 80% scalp hair coverage, versus none on placebo. For the overall study population at week 52, 25.8% on low dose and 27.6% on high dose reached SALT ≤20 compared with 6.7% on placebo, and 30.2% and 35.0% reached SALT ≤30 versus 8.4% on placebo. Clinically meaningful improvements (SALT50 and SALT30) were also higher with rezpegaldesleukin, and 94% of patients in the extension completed 52 weeks. Safety remained favorable, with nearly all adverse events mild to moderate, low discontinuation due to adverse events, and mainly transient injection site reactions. The company states that these data support advancing rezpegaldesleukin into late-stage development in alopecia areata.
Nektar Therapeutics Schedule 13G shows Two Seas Capital and related filers report beneficial ownership of 1,959,178 shares of Common Stock, equal to 6.8% of the class. The stake is held by Two Seas Global (Master) Fund LP and reported with voting and dispositive power held solely by the reporting entities.
The percentage is calculated using 28,687,963 shares outstanding as of March 11, 2026, per the issuer's Form 10-K; filings are signed by Sina Toussi on behalf of the reporting parties.
The Vanguard Group filed an amendment to a Schedule 13G/A reporting 0% beneficial ownership of Nektar Therapeutics common stock. The filing states Vanguard completed an internal realignment effective January 12, 2026, after which certain subsidiaries report holdings separately in reliance on SEC Release No. 34-39538. The amendment is signed on 03/27/2026.
Filer submitted a Form 144 notice to sell Common Stock on 03/13/2026. The filing lists proposed cash sales of Common shares tied to stock option exercises: 28,848, 44,250, and 5,412 shares, each dated 03/13/2026.
The broker listed is Fidelity Brokerage Services LLC. The excerpt shows a dollar figure $5,702,966.40 and a numeric entry 28,687,963, both included verbatim in the excerpt.